** Shares of cancer diagnostic maker Grail GRAL.O falls 3% to $37.16
** Ningi Research says it is short on Grail's position citing co's "overly ambitious approach" to cancer screening that has created "insurmountable regulatory roadblocks"
** "We believe Grail's cancer detection test is backed by data that is just enough to create investor hype, but far too weak to convince experts, regulators, or insurers of its clinical utility," says Ningi in its report
** Ningi says co's actual sales have "massively underperformed projections"
** GRAL stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.